Inmune Bio, Inc.
Business
INmune Bio is a clinical-stage biotechnology company developing immunotherapeutics to reprogram the innate immune system and address diseases driven by chronic inflammation and immune dysfunction. The company's lead program is CORDStrom, a pooled human umbilical cord-derived mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), which completed a pivotal clinical trial and is advancing toward regulatory submission. The pipeline includes XPro, a protein therapeutic targeting neuroinflammation in Alzheimer's disease, and INKmune, a natural killer cell-priming platform for oncology indications, with development activities in the United States, European Union, and United Kingdom.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| REVENUE | 50,000 | 14,000 | 155,000 | 374,000 | 181,000 | |
| General and administrative | 10 | 9 | 10 | 9 | 9 | |
| Research and development | 21 | 33 | 20 | 17 | 21 | |
| Impairment of acquired in-process research and development intangible assets | 17 | — | — | — | — | |
| Total operating expenses | 47 | 43 | 30 | 26 | 29 | |
| LOSS FROM OPERATIONS | −47 | −43 | −30 | −26 | −29 | |
| OTHER INCOME, NET | 1 | 553,000 | −267,000 | — | −1 | |
| NET LOSS | −46 | −42 | −30 | −27 | −30 | |
| Net loss per common share basic (in Dollars per share) | −1.86 | −2.11 | −1.67 | −1.52 | −1.88 | |
| Net loss per common share diluted (in Dollars per share) | −1.86 | −2.11 | −1.67 | −1.52 | −1.88 | |
| Weighted average number of common shares outstanding basic (in Shares) | 25 | 20 | 18 | 18 | 16 | |
| Weighted average number of common shares outstanding diluted (in Shares) | 25 | 20 | 18 | 18 | 16 | |
| Gain (loss) on foreign currency translation | −162,000 | 224,000 | −100,000 | −700,000 | −10,000 | |
| Total comprehensive loss | −46 | −42 | −30 | −28 | −30 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 25 | 21 | 36 | 52 | 75 | |
| Research and development tax credit receivable | 4 | 1 | 2 | — | — | |
| Other tax receivable | 257,000 | 228,000 | 537,000 | 362,000 | — | |
| Prepaid expenses and other current assets | 595,000 | 331,000 | 2 | 4 | 14,000 | |
| TOTAL CURRENT ASSETS | 30 | 23 | 40 | 65 | 83 | |
| Equipment, net | 955,000 | — | — | — | — | |
| Operating lease right of use asset | 914,000 | 307,000 | 414,000 | 507,000 | 726,000 | |
| Other assets | 595,000 | 79,000 | 131,000 | 99,000 | 99,000 | |
| Acquired in-process research and development intangible assets | — | 17 | 17 | 17 | 17 | |
| TOTAL ASSETS | 32 | 40 | 57 | 82 | 100 | |
| Accounts payable and accrued liabilities | 8 | 7 | 8 | 5 | 4 | |
| Deferred liabilities | — | 517,000 | 489,000 | 616,000 | 474,000 | |
| Operating lease, current liability | 623,000 | 140,000 | 119,000 | 87,000 | 72,000 | |
| TOTAL CURRENT LIABILITIES | 8 | 7 | 18 | 11 | 4 | |
| Long-term operating lease liability | 411,000 | 244,000 | 397,000 | 526,000 | 704,000 | |
| TOTAL LIABILITIES | 9 | 7 | 19 | 22 | 20 | |
| COMMITMENTS AND CONTINGENCIES | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding | — | — | — | — | — | |
| Common stock, $0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively | 27,000 | 22,000 | 18,000 | 18,000 | 18,000 | |
| Additional paid-in capital | 233 | 196 | 159 | 152 | 144 | |
| Accumulated other comprehensive loss | −737,000 | −575,000 | −799,000 | −699,000 | 1,000 | |
| Accumulated deficit | −209 | −163 | −121 | −91 | −64 | |
| TOTAL STOCKHOLDERS EQUITY | 24 | 32 | 37 | 60 | 80 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 32 | 40 | 57 | 82 | 100 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 10 | 8 | 7 | 7 | 5 | |
| Accretion of debt discount | 0 | 79,000 | — | — | — | |
| Gain on settlement of accounts payable | −626,000 | — | — | — | — | |
| Depreciation expense | 84,000 | — | — | — | — | |
| Research and development tax credit receivable | −3 | 724,000 | 6 | — | — | |
| Other tax receivable | −29,000 | 309,000 | −175,000 | 229,000 | −478,000 | |
| Prepaid expenses and other current assets | −264,000 | 1 | — | −2 | −2 | |
| Prepaid expenses related party | 0 | 142,000 | −108,000 | — | — | |
| Other assets | −516,000 | 52,000 | −32,000 | — | −99,000 | |
| Accounts payable and accrued liabilities | 2 | −1 | 3 | 1 | 2 | |
| Accounts payable and accrued liabilities related parties | — | −10,000 | 26,000 | −71,000 | 46,000 | |
| Deferred liabilities | −517,000 | 28,000 | −127,000 | 142,000 | — | |
| Operating lease liability | 43,000 | −25,000 | −4,000 | −33,000 | 46,000 | |
| Net cash used in operating activities | −23 | −33 | −12 | −23 | −29 | |
| Purchase of fixed assets | −1 | — | — | — | — | |
| Net cash used in investing activities | −1 | — | — | — | −15 | |
| Net proceeds from sale of common stock and warrants | 28 | 28 | 775,000 | 699,000 | 80 | |
| Cash proceeds for amendment of warrants | 67,000 | — | — | — | — | |
| Exercise of warrants for cash | 1,000 | — | — | 30,000 | 18,000 | |
| Repayment of debt | — | −10 | −5 | — | — | |
| Net proceeds from the exercise of stock options | — | 422,000 | — | — | 1 | |
| Net cash provided by financing activities | 28 | 18 | −4 | 729,000 | 96 | |
| Impact on cash from foreign currency translation | −159,000 | 224,000 | −100,000 | −700,000 | −10,000 | |
| NET INCREASE (DECREASE) IN CASH | 4 | −15 | −16 | −23 | 53 | |
| Cash paid for income taxes | — | — | — | — | — | |
| Cash paid for interest expense | — | 2 | 2 | 1 | 559,000 | |
| Right of use assets obtained in exchange for lease obligations | 702,000 | — | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Inmune Bio, Inc.'s CIK number?
Inmune Bio, Inc.'s SEC CIK number is 0001711754 (1711754). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Inmune Bio, Inc.'s SEC filings?
All of Inmune Bio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Inmune Bio, Inc. last report earnings?
Inmune Bio, Inc. (INMB) most recently filed an earnings 8-K with the SEC on Oct 30, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-25-104154). This is Inmune Bio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Inmune Bio, Inc.'s most recent earnings 8-K?
Inmune Bio, Inc.'s latest earnings 8-K (Item 2.02) was filed Oct 30, 2025 under accession 0001213900-25-104154. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Inmune Bio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →